药明生物(02269.HK)离岸合资药明海德香港引入战投海利生物(603718.SH)实现强强联合
格隆汇8月29日丨药明生物(02269.HK)公布,于2019年5月24日,公司已成立离岸合资公司WuXi Vaccines (Hong Kong) Limited(药明海德香港有限公司);同时于2019年8月29日,药明生物投资及离岸合资公司(两者均为公司全资附属公司)与海利生物(603718.SH)订立股份转让协议,据此,药明生物投资同意按名义对价转让其所持有的离岸合资公司全部已发行股本的30%(即转让股份)予海利生物。
完成后,(i)离岸合资公司将分别由药明生物投资及海利生物拥有70%及30%股权;及(ii)离岸合资公司将继续为公司的附属公司。于本公告日期,离岸合资公司并无业务营运或资产。离岸合资公司计划将主要从事疫苗CDMO业务,建设集疫苗原液(DS)及制剂(DP)生产、质量控制(QC)实验室于一体的综合疫苗生产基地,并为全球市场生产及供应疫苗。
为满足未来资金需要,药明生物投资与海利生物(作为股东)可按股权比例进一步向离岸合资公司注资,时间及金额由离岸合资公司厘定,上限分别为9800万美元及4200万美元。
公司称,透过股份转让,公司与海利生物将能相辅相乘,强强联合,齐力促进离岸合资公司未来业务发展。继成立离岸合资公司后,订立股份转让协议为公司疫苗CDMO业务的又一突破性进展。董事相信,股份转让符合公司整体发展策略,紧抓疫苗CDMO业务的发展机遇,有利于医疗行业的发展及公司持续增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.